NDAORALTABLET1 Generic Approved
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
15/100
Clinical Trials
10
Data completeness
7/8 — Comprehensive
FERRIPROX (deferiprone) by Chiesi is iron chelating activity [moa]. Approved for iron chelator [epc]. First approved in 2020.
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FERRIPROX (deferiprone) is an oral iron chelator approved in 2020 for managing iron overload in patients with chronic transfusion-dependent conditions such as thalassemia and sickle cell disease. It works by binding excess iron and facilitating its elimination through urine and feces. This small-molecule therapeutic addresses a critical unmet need in rare hematologic diseases where iron accumulation causes organ damage.
$4MPart D
Peak12.0 years to LOEFERRIPROX is in peak commercial stage with modest Part D spending; teams are focused on market penetration and maintaining share against established competitors in a niche but stable indication.
Mechanism of Action
Iron Chelating Activity
Pharmacologic Class:
Iron Chelator
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia
Started Aug 2026
80 enrolled
Schizoaffecitve DisorderSchizophrenia and Schizoaffective DisorderSchizophrenia and Predominant Negative Symptoms
Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload
Started Mar 2019
30 enrolled
Iron Overload Due to Repeated Red Blood Cell Transfusions
Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
Started Nov 2018
64 enrolled
Beta Thalassemia Major AnemiaIron Overload
Study of Parkinson's Early Stage With Deferiprone
Started Oct 2016
140 enrolled
Parkinson's Disease
Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias
Started May 2015
134 enrolled
Iron OverloadSickle Cell DiseaseOther Anemias
Worked on FERRIPROX at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.